BSX Reports: CEO Still Underwater, Analysts Cut Again

Boston Scientific reported third-quarter results today, October 28, with the stock at $45.06, still roughly 7% below the $48.33 price at which CEO Michael Mahoney bought $9 million of shares in a single discretionary transaction this August.

The insider story remains the defining tension on this name. Mahoney's open-market purchase of 186,240 shares, made without a 10b5-1 plan, was the largest discretionary CEO buy visible in public filings over the summer. Two directors and the CFO added positions across August as well, pushing 90-day net insider buying to approximately $9.5 million across roughly 200,000 net shares. That cluster of unplanned purchases, at the CEO level, represents one of the more concrete conviction signals available from Form 4 filings. The stock has not yet recovered to those entry levels.

The sell-side moved in the opposite direction on earnings day. Needham's Mike Matson cut his target from $57 to $48 this morning while holding a Buy rating, making him the latest in a string of cuts. Stifel trimmed from $60 to $55 on October 26. Truist cut from $57 to $51 on October 14. The consensus mean target is $57.82, which would represent roughly 28% upside from here, but that figure is being dragged down with each revision. The bull case rests on a projected expansion of the global AFib market from $9 billion to $15 billion by 2028, with procedure volumes expected to grow as new catheter technology gains adoption. The bear case points to declining market share in radiofrequency ablation, where RF procedures are forecast to fall from 34% to 23% of the mix by 2030, combined with pricing pressure and a debt load that limits operating leverage. EPS momentum factor scores rank in the 18th to 21st percentile over the past 30 and 90 days, reflecting the weight of downward revisions. ORTEX factor scoring also places analyst recommendation differentiation near the bottom of the universe, a sign that the Street's Buy-rated analysts are not broadly upgrading their conviction alongside their targets.

Short interest is not a meaningful angle here. At 2.9% of the free float, it sits well below levels that signal active short conviction. The borrow market reinforces that view. Availability is effectively unconstrained, with over 1.4 billion shares available to lend. Cost to borrow has fallen 42% over the past week to 0.26%, near the lowest level of the past 30 days. There is no lending market pressure on this stock in either direction. Options positioning is similarly quiet, with the put/call ratio at 0.41, just below its 20-day average of 0.43 and a fraction below neutral on a z-score basis. Neither the borrow market nor the options market is pricing in stress.

One forward-looking structural factor worth tracking is the Penumbra acquisition. ORTEX puts an 84% probability on a Russell 1000 and Russell 3000 share-count increase by mid-December, and 65% odds of a similar adjustment in the MSCI World and FTSE All-World indices, both tied to the PEN takeover being agreed. The CRSP US Mid index rebalance in December carries a 75% probability of a share increase there, with an estimated $635 million of tracker buying. Separately, ORTEX forecasts a 75% chance of deletion from the CRSP US Mega index at the same December review, reflecting where the current $65.3 billion market cap sits relative to the $75.9 billion threshold that keeps it in that index. These are mechanical flows, not a directional view on the stock, but the December rebalance window is a concrete date for passive money to move.

Wikipedia attention for BSX registered a z-score of 1.32 against its own 90-day history in the week ending October 21, the highest retail-attention reading visible in the dataset, consistent with earnings-day interest rather than a lasting shift in sentiment.

What to watch now is whether today's third-quarter print, reported this morning, gives the CEO's August entry price any fundamental support, or whether the result reinforces the pattern of estimate cuts that has defined the analyst response since the summer.